Cardiawave
Developer of a non-invasive therapeutic ultrasound approach for treatment of calcific aortic stenosis. The organisation conducts clinical studies, pursues regulatory approvals and publications, manages intellectual property, and has received public research funding to support device development and clinical deployment.
Industries
Nr. of Employees
small (1-50)
Cardiawave
Levallois-Perret, Île-de-France, France
Patents
Process for testing the accuracy and the performance of an ultrasound transducer
US-12605569-B2
View DetailsUltrasonic processing apparatus comprising means for imaging cavitation bubbles
US-11571230-B2
View Details
Process for testing the accuracy and the performance of an ultrasound transducer
US-12605569-B2
View DetailsUltrasonic processing apparatus comprising means for imaging cavitation bubbles
US-11571230-B2
View DetailsProducts
CE-marked non-invasive therapeutic ultrasound system for calcific aortic stenosis
A medical device system that delivers targeted ultrasound intended to soften calcified aortic valve tissue as a non-surgical treatment option.
CE-marked non-invasive therapeutic ultrasound system for calcific aortic stenosis
A medical device system that delivers targeted ultrasound intended to soften calcified aortic valve tissue as a non-surgical treatment option.
Services
Planning and running clinical studies for a non-invasive ultrasound therapy with publication and conference presentation of results.
Support for adoption and initiation of routine treatments at hospital sites following regulatory approval.
Planning and running clinical studies for a non-invasive ultrasound therapy with publication and conference presentation of results.
Support for adoption and initiation of routine treatments at hospital sites following regulatory approval.
Expertise Areas
- Therapeutic ultrasound development
- Clinical trial management
- Medical device regulatory affairs (CE marking)
- Clinical deployment and hospital partnerships
Key Technologies
- Therapeutic ultrasound
- Non-invasive cardiac valve therapy
- Clinical trial methodologies for medical devices
- Medical device regulatory pathways (CE marking)
News & Updates
Announcement of first routine clinical treatments performed after CE marking and acceleration of device deployment.
Publication announcing receipt of CE marking for a non-invasive treatment for severe symptomatic aortic stenosis.
Announcement of positive 6-month data from the pivotal clinical study presented at a major cardiology conference.
Announcement of positive 12-month clinical results from early and pivotal studies presented at EuroPCR.
Results from clinical studies published in a peer-reviewed journal.
Three new patents granted extending intellectual property protection in the United States.
Announcement of first routine clinical treatments performed after CE marking and acceleration of device deployment.
Publication announcing receipt of CE marking for a non-invasive treatment for severe symptomatic aortic stenosis.
Announcement of positive 6-month data from the pivotal clinical study presented at a major cardiology conference.
Announcement of positive 12-month clinical results from early and pivotal studies presented at EuroPCR.
Results from clinical studies published in a peer-reviewed journal.
Three new patents granted extending intellectual property protection in the United States.